BamSEC and AlphaSense Join Forces
Learn More

SCYNEXIS Inc. – Material Contracts

NASDAQ: SCYX    
Share price (6/11/26): $4.25    
Market cap (6/11/26): $42.2 million

Material Contracts Filter

EX-10.1
from 10-Q 69 pages Asset Purchase Agreement Between Scynexis, Inc., as Buyer and Poxel SA as Seller Dated as of March 30, 2026
12/34/56
EX-10.2
from 8-K 25 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 44 pages Securities Purchase Agreement
12/34/56
EX-10.31
from 10-K 6 pages Binding Memorandum of Understanding for Amendment to Exclusive License Agreement
12/34/56
EX-10.17
from 10-K 3 pages SCYNEXIS Non-Employee Director Compensation Policy
12/34/56
EX-10.2
from 10-Q 3 pages Scynexis Non-Employee Director Compensation Policy Revised April 2024
12/34/56
EX-10.1
from 10-Q 18 pages Employment Agreement
12/34/56
EX-10.41
from 10-K 13 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential
12/34/56
EX-10.21
from 10-K 3 pages Scynexis Non-Employee Director Compensation Policy Revised December 2023; Effective January 1, 2024
12/34/56
EX-10.3
from 10-Q 3 pages Third Amendment to Termination and License Agreement
12/34/56
EX-10.2
from 10-Q 4 pages Second Amendment to Termination and License Agreement
12/34/56
EX-10.1
from 10-Q 2 pages December 3, 2014 By:___/S/ Iain Dukes 12/11/14 Name:___iain Dukes Title:___svp, Research Science
12/34/56
EX-10.1
from 10-Q 8 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Redacted Pursuant to Item 601(a)(6) of Regulation S-K
12/34/56
EX-10
from 10-Q 9 pages October 20, 2022 Christine Rose Coyne
12/34/56
EX-10
from 10-Q 129 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential. Exclusive License Agreement by and Between Scynexis, Inc. and Glaxosmithkline Intellectual Property (No. 3) Limited Dated as of March 30, 2023
12/34/56
EX-10
from 10-K 17 pages Employment Agreement
12/34/56
EX-10
from 10-K 18 pages Employment Agreement
12/34/56
EX-10
from 10-K 7 pages October 20th, 2022 1. Separation. Your Last Day of Work With the Company and Your Employment Termination Date Will Be December 31, 2022 (The “Separation Date”). 2. Accrued Salary and Paid Time Off. by the Date Required by Applicable Law, the Company Will Pay You All Accrued Salary and All Accrued and Unused Vacation Earned Through the Separation Date, Subject to Standard Payroll Deductions and Withholdings. You Are Entitled to This Payment by Law. 3. Separation Benefits. Although the Company Has No Obligation to Do So, if You Timely Sign This Agreement, Allow It to Become Effective, and Comply With Your Obligations Under It (Collectively, the “Separation Preconditions”), Then
12/34/56
EX-10.2
from 10-Q 11 pages Scynexis, Inc. Restricted Stock Unit Award Grant Notice 2015 Inducement Award Plan
12/34/56
EX-10.1
from 10-Q 27 pages Scynexis, Inc. 2015 Inducement Award Plan Adopted: March 26, 2015 Amended: June 9, 2019 Adjusted for Reverse Stock Split: July 17, 2020 Further Amended: April 30, 2021 Further Amended: October 18, 2022
12/34/56